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Abstract Testis cancer is the most frequent solid malig-
nancy in young men. The majority of patients present with
clinical stage I disease and about 50% of them are nonse-
minomatous germ cell tumors. In this initial stage of dis-
ease there is a subgroup of patients at high risk with a
likelihood of more than 50% for relapse. Treatment options
for these patients include: retroperitoneal lymph node dis-
section (RPLND), albeit 6–10% of patients will relapse
outside the Weld of RPLND, active surveillance with even
higher relapse rates and adjuvant chemotherapy. As most of
these patients have the chance to become long-term survi-
vors, avoidance of long-term side eVects is of utmost
importance. This review provides information on the poten-
tial of chemotherapy to achieve a higher chance of cure for
patients with high-risk clinical stage I disease than its
therapeutic alternatives and addresses toxicity and dose
dependency.
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Introduction
The introduction of cisplatin-based chemotherapy has made
testis cancer a highly curable disease. Testis cancer repre-
sents the most frequent malignant solid tumor in young
men and 90% of patients present with clinical stage I
disease and normal tumor markers after orchiectomy [1].
Of these, half of patients are diagnosed with nonseminoma-
tous germ cell tumor (NSGCT) of the testis. Treatment
options include surveillance with deferred chemotherapy in
case of relapse, retroperitoneal lymph node dissection
(RPLND) or two courses of bleomycin, etoposide and cis-
platin (BEP) chemotherapy, but the preferred management
of clinical stage I NSGCT still remains controversial.
Although therapeutic approaches diVer between countries
and institutions, there seems to be no diVerence in the
excellent long-term survival rates of 97% or more.
Only 30% of patients have occult metastatic disease
found at RPLND, making either routine chemotherapy or
RPLND potentially unnecessary therapeutic burdens.
To minimize unnecessary overtreatment, risk stratiWca-
tion for patients at high risk for harboring undetectable
metastases were developed in order to administer early
adjuvant therapy only to those who most likely need it.
Subsequently, a risk-adapted strategy based on the absence
or presence of risk factors in the orchiectomy specimen has
been recommended as standard procedure [2].
In this review we focus on the role of chemotherapy in
patients at high risk to develop metastatic disease and dis-
cuss the pros and cons of established alternative treatment
options.
Prognostic risk factors
With the exception of choriocarcinoma and yolk sac tumors
that metastasize mainly via hematogenous routes, NSGCTs
follow a well known and predictable route of metastatic
spread based on the lymphatic drainage of the testes to the
retroperitoneal lymph nodes, and eVorts have been made to
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Computed tomography (CT) is only able to distinguish
metastatic nodes by size. Newer imaging techniques such
as 18-FDG-PET now have additional ability over CT to
detect patients at high risk for relapse [3]. As the presence
of occult retroperitoneal metastases cannot be reliably ruled
out due to inaccuracy of clinical staging methods, multiple
studies have been conducted to identify risk factors for
pathologic stage II A disease.
In 1987 a multivariate analysis performed by the Medi-
cal Research Council (MRC) identiWed four histopatho-
logic features of the primary tumor that predicted relapse:
vascular invasion, lymphatic invasion, absence of yolk sac
elements and presence of undiVerentiated tumor [4]. On the
basis of these features another MRC trial was conducted
that showed a recurrence rate of approximately 50% when
three or four of these risk factors were present with vascular
invasion (VI) being the most important [5].
In a prospective trial of the German Testicular Study
Group, 200 patients were assigned to RPLND [6]. Twenty-
eight percent of patients were found to have retroperitoneal
disease and again VI was the most predictive variable with
a positive predictive value (PPV) of 52.7%. This was
increased to 63.7% by adding the MIB score ¸70% and
percentage of embryonal carcinoma (EC) >50%. Patients at
low risk for relapse could be identiWed with a negative pre-
dictive value of 86.5%, rendering them good candidates for
surveillance.
Moul et al. analyzed 92 patients with clinical stage I
NSGCT for histological risk factors. The probability of
occult disease rose from 4% in patients without embryonal
components and no VI to 67% in patients with 50% EC and
VI, and up to 92% in patients with pure EC and VI. This
gave an almost linear relationship between the percentage
of EC and retroperitoneal disease [7]. Other models con-
Wrmed the inXuence of percentage of EC (·45%, 46–79%,
¸80%) and VI, with odds ratio (OR) of 2.1–7.4 and 8.2–9.0
for the percentage of EC 46–79% and ¸80%, respectively
[8, 9].
Similar results were published by the Indianapolis group
who reported a 46.5% risk of pathological stage II disease
when EC predominance and VI were present in the orchiec-
tomy specimen [10].
Several study groups showed that VI, higher pT-stage
(pT2–4 vs. pT1) and EC predominance were most predic-
tive of pathological stage II and the risk of recurrence
ranged between 32 and 76%. In a meta-analysis pT-stage
and presence of embryonal carcinoma had moderate eVects,
but MIB-1 staining >70% was a promising predictor for
relapse (OR 4.7) [11]. Other molecular markers such as
p53, bcl-2, cathepsin D and E-cadherin have little predic-
tive value when compared to VI [8].
In summary, several risk factors have been identiWed; VI
and EC are the most powerful predictors for relapse allow-
ing for a risk-adapted treatment. High-risk groups bear a
risk of recurrence of approximately 50–60% and low-risk
groups of 13–16%.
Evolution of primary chemotherapy in high-risk 
clinical stage I NSGCT
Patients with clinical stage I NSGCT and a high risk of
relapse may be cured with chemotherapy. In Europe two
courses of BEP are considered the standard treatment
option [2]. With this therapeutic approach cure rates of
about 98% are reached.
In 1992 Oliver published the Wrst results of two courses
of BEP chemotherapy for patients at intermediate and high
risk to develop metastatic disease. Adjuvant chemotherapy
was oVered when two or more of the high-risk features—
VI, lymphatic invasion, presence of undiVerentiated cells,
absence of yolk sac tumor elements—were presented.
Twenty-one of 22 patients (95.5%) remained free of metas-
tases. One patient relapsed and died of progressive disease
[12].
One year later Studer et al. presented the medium-term
results of two courses of adjuvant BEP in a larger series and
longer follow-up of patients with clinical stage I NSGCT.
In this trial VI, stage >pT1 or the presence of EC were risk
factors required for patient eligibility. After a median fol-
low-up of 42 months 40 of 41 patients (97.6%) remained
relapse free. One patient underwent surgical excision of
mature teratoma 26 months after orchiectomy and was dis-
ease-free thereafter [13]. These results were updated by
Bohlen in 1999 [14].
An Austrian group administered two cycles of BEP
polychemotherapy in patients with clinical stage I NSCGT
and evidence of VI in the primary tumor [15]. After a
median follow-up of 79 months 2 of 29 (6.9%) patients had
relapsed and one of them died of progressive disease.
In a multicenter UK Medical Research Council study
presented in 1996, 114 eligible patients featuring at least
three of the four risk factors (VI, lymphatic invasion, pres-
ence of undiVerentiated cells, absence of yolk sac tumor
elements) received two cycles of BEP [16]. Only two
relapses were reported after a follow-up of at least 2 years.
The Spanish Germ Cell Group conWrmed these data in a
well conducted prospective trial in which 589 patients
entered a risk-adapted protocol after orchiectomy. Two
hundred and thirty-one patients with the high-risk factors of
VI or local inWltration of adjacent structures received two
courses of BEP, while patients at low risk for relapse were
kept under surveillance. In the chemotherapy group two123
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vage therapy [17].
Similar results were published by Klepp, Ondrus, Hen-
dry, Boehlen, Chevreau and Amato with 34, 18, 60, 60, 40
and 76 patients at high risk for occult metastatic disease.
Risk factors were slightly diVerent from study to study but
included mainly the accepted histologic features known to
be predictive for relapse. Recurrences occurred in 0–3% of
cases with excellent long-term survival rates [14, 18–22].
The Medical Research Council piloted a new regimen with
two courses of cisplatin, vincristine and bleomycin (BOP)
in clinical stage I high-risk patients intending to eliminate
the toxicities of etoposide. The 5-year relapse-free rate of
98.3% in 115 patients was equivalent to that of the BEP
regimen, but neurotoxicity was present in 12% after 2 years
and the authors could not show any clear-cut advantages of
BOP over the BEP regimen [23].
Hoping to cure patients with a lesser cytotoxic treatment,
the Swiss Group for Clinical Cancer Research recently
completed a protocol with one single course of BEP che-
motherapy for high-risk clinical stage I NSGCT [24]. After
a median follow-up of 99 months, 36 of 37 evaluable
patients with VI and/or EC predominance (>50%) remained
relapse-free with one possibly treatment-related death with
acute respiratory distress syndrome shortly after salvage
chemotherapy.
Lately, the German Testicular Cancer Study Group pub-
lished the results in 382 patients with clinical stage I
NSGCT randomized to either RPLND or one cycle of BEP
chemotherapy without consideration of risk factors. VI was
present in 138 patients (42%) and was evenly distributed
between the two treatment groups. The oncological out-
come of this high-risk subpopulation was not determined in
the study. The overall diVerence in the 2-year recurrence-
free survival rate between chemotherapy and surgery, how-
ever, was 7.04% in favor of chemotherapy, and the hazard
ratio to sustain tumor relapse with RPLND was 7.937 (95%
CI, 1.808–34.48). This is the Wrst randomized trial that
proved a superior outcome for one single course of adju-
vant chemotherapy over RPLND in clinical stage I
NSGCT. Nevertheless, there is a relatively high surgical
failure rate after RPLND with seven retroperitoneal and
two inguinoscrotal recurrences. Adequacy of RPLND was
less than expected in this 61-center trial in which many sur-
geons performed relatively few procedures. This Wnding
again strongly suggests that RPLND should be performed
in specialized high-volume centers only to minimize recur-
rences.
An overview on the results reported with adjuvant che-
motherapy for high-risk clinical stage I NSGCT is pre-
sented in Table 1.
Adjuvant chemotherapy in perspective 
to other treatment modalities
Since success rates of the established treatment modalities
surveillance, RPLND and adjuvant chemotherapy are
Table 1 Chemotherapy for with high-risk clinical stage I NSGCT
BEP bleomycin, etoposide, cisplatin; BE bleomycin, etoposide; PVB bleomycin, vincristine, cisplatin; CEB carboplatin, etoposide, bleomycin;
PVB cisplatin, vinblastine, bleomycin; RF risk factor; DOD dead of disease
Risk factors: VI vascular invasion; LI lymphatic invasion; EC embryonal carcinoma; ECP embryonal carcinoma predominance; MRC risk factors
vascular invasion, lymphatic invasion, absence of yolk sac tumor, presence of undiVerentiated cells; AFP normal pre-orchiectomy AFP serum level
a Contralateral testis cancer excluded
First author Year Chemotherapy Risk factors No. of patients 
(evaluable/all)
Relapse 
ratea
DOD
Oliver [12] 1992 2 BEP ¸2 MRC RF 22/22 1 (4.5%) 1 (4.5%)
Cullen [16] 1996 2 BEP ¸3 MRC RF 109/114 2 (1.8%) 1 (0.9%)
Pont [15] 1996 2 BEP VI+ 29/42 2 (6.9%) 1 (3.4%)
Klepp [20] 1997 3 BEP VI+ and AFP¡ 32/34 1 (3%) 0
Ondrus [21] 1998 2 BEP VI+ and/or ECP 18/18 0 0
Bohlen [14] 1999 2 BEP or PVB VI+ and/or LI+ and/or ¸pT2 and/or EC+ 58/60 1 (1.7%) 0
Hendry [22] 2000 2 BEP ¸3 MRC RF 60/60 1 (1.7%) 1 (1.7%)
Chevreau [19] 2004 2 BEP VI+ and/or LI+ and/or EC+ 36/40 0 0
Amato [18] 2004 CEB 1 or more RF: AFP >80 ng/dl, >80% EC, VI, LI 68/76 1 (1.5%) 0
Maroto [17] 2005 2 BEP VI and/or EC+ and/or invasion of local structures 231/231 2 (0.9%) 0
Dearnaley [23] 2005 2 PVB VI+ and/or LI+ 115/115 2 (1.7%) 1 (0.9%)
Westermann [24] 2008 1 BEP VI+ and/or LI+ and/or ECP 37/40 1 (2.7%) 1 (2.7%)
Albers [31] 2008 1 BEP VI in 41.8% of patients 174/191 2 (1.1%) 0
Total 989/1043 16 (1.6%) 6 (0.6%)123
458 World J Urol (2009) 27:455–461similar, focus has changed toward minimizing treatment-
related morbidity by maintaining oncological eYcacy.
RPLND is considered the best staging procedure by
many US authors and has excellent long-term results and
high cure rates, even in case of relapse [10, 25]. Further-
more, it simpliWes postoperative follow-up with less fre-
quent abdominal CTs, as recurrence predominantly occurs
outside the limits of the surgical templates. Major disad-
vantages are that about 50% of all high-risk clinical stage I
cancers are overtreated with RPLND and that 8–29% of
patients experience relapse. This is mainly in the mediasti-
num, even in case of lymph node-negative disease, indicat-
ing that metastases bypass the retroperitoneum [10, 26].
The 29% rate of distant metastases in high-risk patients
with EC predominance and VI in the primary tumor follow-
ing RPLND, despite histologically negative nodes, is far
higher than in the low-risk group, where metastases occur
in only 4–6% of cases [10, 26]. Therefore, meticulous
removal of the retroperitoneal lymph nodes cannot prevent
recurrence in all cases and still requires a costly and careful
patient follow-up. In addition, as a signiWcant number of
patients with clinical stage I–IIA NSGCT and retroperito-
neal metastases present with extratemplate disease, an
extensive RPLND is a must [27]. Of patients with clinical
stage I, but pathological stage IIA disease, 20–40% will
relapse if left untreated after RPLND and will require three
to four courses of intensive platinum-based induction che-
motherapy [28, 29]. In such cases cytotoxic morbidity is
increased. Thus, the data from the most experienced centers
show that RPLND often is not curative when negative or
positive nodes have been removed [30], and the rationale
for lymph node dissection in the latter patient group is more
than questionable. Furthermore, surgical complications
occur in 5–14%. Only in experienced hands are postopera-
tive morbidity and ejaculatory dysfunction rates low. In
inexperienced hands recurrence and death after RPLND
may occur [31].
Active surveillance in clinical stage I NSGCT is the only
way to avoid unnecessary over treatment. Non-risk-adapted
surveillance protocols have shown relapse rates of 17–38%
due to undetected micrometastases, 17–30% in the retroper-
itoneum and about 10% above to the diaphragm [4, 5, 32,
33]. In patients with high-risk testicular cancer relapse rates
rise to 52–75.7% [32–34], and patients may be under con-
siderable psychological stress due to this. Patients experi-
encing progressive disease must be exposed to the toxicity
of three to four cycles of intensive chemotherapy [22] and
despite appropriate salvage therapy, 1–2% of them die of
progressive disease. Therefore, surveillance protocols in
patients featuring high-risk factors have been abandoned by
several authors. In addition, post-chemotherapy RPLND
which may be necessary for residual masses after salvage
chemotherapy is associated with higher acute morbidity
and reduced preservation of ejaculatory function in 60% of
cases [35].
Most relapses occur within the Wrst 2 years after diagno-
sis. Therefore, high patient compliance is mandatory not
only during this early period of time to detect recurrence at
an early stage, but also for many years, as 5–10% of
patients develop late relapse. Frequent abdominal and tho-
racic CT or MRI scans are essential for adequate follow-up.
In a Canadian multicenter surveillance program the rate of
compliance was as low as 64% for CT scanning during the
Wrst 2 years [36]. Compliance was highest in centers with
protocols requiring the least frequent visits, but especially
surveillance programs require close follow-ups.
An additional disadvantage of repeat CT examinations is
the exposure of the patients to a considerable radiation
dose. After 10 CT scans, which are usually required for a
“wait and watch” policy, an estimated 5 of 1,000 men may
develop a radiation-induced secondary malignancy. Con-
sidering the current and future CT use, the estimated risk
may rise to 1.5–2.0% [37]. These data are supported by
Chamie et al., who reported on 3,334 patients who chose
active surveillance or RPLND for clinical stage I NSGCT.
Of these, 172 developed a secondary malignant neoplasm
(SMN) after a median follow-up of 16.4 years. Patients
under surveillance developed secondary radiation-induced
malignancies 1.74 times more frequently than those who
underwent RPLND [38]. In addition, also patients without
adjuvant therapy face the risk of late toxicity and malignant
transformation.
Men with curable testis cancer are long-term survivors.
This fact weighs heavily on chemotherapy-related toxicity.
Acute and long-term side eVects have always strengthened
the case against adjuvant chemotherapy and for RPLND, as
cisplatin-based cytotoxic treatment is often associated with
nephrotoxicity, cardiotoxicity and ototoxicity.
Nephrotoxicity may occur to some degree in patients
who receive cisplatin, but it is rare when administered with
adequate hydration [14]. Even in patients with disseminated
germ cell tumors and poor prognosis treated with high-dose
VIP (etoposide, ifosfamide, cisplatin), renal failure is as
low as 3% [39]. Nephropathy is compensated with only
serum creatinine elevation and no elevation of other reten-
tion parameters.
Concerning cardiotoxicity, no association was found
between chemotherapy and an increased risk for cardiovas-
cular disease in clinical stage I or II patients treated with
surgery alone or surgery and chemotherapy. In addition, no
elevated risk for myocardial infarction (MI) in more than
2,500 5-year survivors of testis cancer was reported for
BEP chemotherapy alone, whereas the MI risk after PVB
(cisplatin, vinblastine, bleomycin) chemotherapy, mediasti-
nal irradiation and recent smoking was increased 1.9, 3.7
and 2.6-fold, respectively [40]. As for ototoxicity, tinnitus123
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patients treated with higher cisplatin doses, but no serious
long-term side eVects were reported in studies using two
BEP cycles for clinical stage I high-risk NSGCT [14–16,
19, 24].
Bleomycin-induced pneumonitis is another rare but
well-known problem, especially when smoking is a co-
existing risk factor. In testis cancer patients treated with
RPLND with or without adjuvant, 3–4 courses of BEP
there was no diVerence in long-term impairment of pulmo-
nary function [41]. To keep pulmonary toxicity as low as
possible, in the Swiss BEP protocols bleomycin was given
as a 24-h infusion and no lung toxicity was reported [14].
The risk for etoposide induced secondary leukemia is an
often cited argument against the use of BEP for NSGCT.
Several studies show a risk of 0.5–1% with cumulative
high-dose etoposide doses >2–8 g/m2 [42]. Modern BEP
regimens remain signiWcantly below this threshold, and no
leukemia was reported at doses <2 g/m2, rendering leuke-
mia a negligible concern for NSGCT patients.
The risks of secondary solid malignancies (SMN) in
2,700 5-year survivors of testis cancer were calculated by
van den Belt-Dusebout. In NSGCT patients receiving che-
motherapy alone, the standardized incidence rate for SMN
was 1.4 (0.9–2.1) compared to patients with surgery alone.
However, patient data were collected from the period
1965–1995 when treatment protocols with two or less
cycles of BEP were not used, and patients were treated with
high-dose chemotherapy. Furthermore, the risk of mela-
noma, which was the predominant SMN followed by blad-
der cancer, was increased not only after chemotherapy
alone, but also after other treatments. This suggested shared
genetic origins with NSGCT instead of treatment causality
[43].
Furthermore, it is unknown whether the development of
a secondary neoplasm is related to an inherent genetic
instability which also originated the testicular cancer [44].
Usually, patients with testis cancer are young at the time
of diagnosis, and fertility is an important aspect. It is known
that 50–70% of testis cancer patients are subfertile or have
impaired spermatogenesis, and even on surveillance alone
pregnancy rates are as low as 46%, because gonadal dys-
function is common in these patients. After 3–4 cycles of
BEP for advanced disease semen quality normalizes fol-
lowing intermittent depression. When only two courses of
chemotherapy are given there is no negative aVect on sperm
counts after 9–12 months [15, 16].
An important argument against adjuvant chemotherapy
is the risk of metastatic adult teratoma to the retroperito-
neum, even if absent in the primary tumor. Teratoma is a
histologically benign slow growing tumor that is resistant
to chemotherapy, and treatment requires complete surgical
excision. Metastatic spread is rare (3%) in clinical stage I
NSGCT [45], and resection is possible before teratomatous
masses cause compression of neighboring structures and
before a late relapse with malignant transformation occurs.
Another point against adjuvant chemotherapy is the risk of
aggressive late relapses in the retroperitoneum. However,
these are only related to the initial tumor burden and occur
after chemotherapy for bulky metastatic disease at Wrst pre-
sentation of patients [46] suggesting incomplete eradication
and selection of chemotherapy-resistant cells. Chemoresis-
tant relapse in clinical stage I NSGCT has not been reported
so far [47].
Once patients at high risk for relapse are identiWed,
occult metastatic disease can be treated by chemotherapy.
The advantage of this strategy is based on the fact that
tumor burden is never as small as right after orchiectomy
and therefore the quantity of cytotoxic drugs necessary can
be reduced to a minimum.
Until now all studies approaching high-risk clinical stage
I NSGCT with two courses of chemotherapy such as BEP
have been shown to eliminate virtually all occult metastases
and to produce excellent survival rates of 98–99%. Long-
term toxicity remains marginal [15, 19, 24] and poor com-
pliance is negligible, since relapse—in contrast to RPLND
or surveillance—is an exception. In addition, double treat-
ment with higher dose salvage chemotherapy after failure
of primary RPLND can be avoided.
These are the reasons why the European Consensus Con-
ference on diagnosis and treatment of germ cell cancer sug-
gests two cycles of adjuvant BEP for patients with high-risk
clinical stage I as a standard [2]. Studies are underway to
elucidate whether even 1 cycle of BEP is suYcient as has
been suggested by preliminary data. [24–26]
Conclusion
Patients with clinical stage I NSGCT at high risk for relapse
have an excellent long-term prognosis independent of the
therapeutic approach used. Surveillance protocols leave the
patients with approximately a 50% risk for relapse. This
exerts a high psychological pressure on patients and exten-
sive chemotherapy in case of relapse if necessary. RPLND
alone is not curative if positive nodes are found and leaves
the patient with a 6–10% risk of progression even if the
nodes are negative. This implies not only substantial over-
treatment for the majority of patients who do not proWt
from RPLND. Patients may also be exposed to unnecessary
morbidity combined with an uncertain cure. In case of
extratemplate recurrence high-dose salvage chemotherapy
is needed. With the intention to minimize morbidity and
maximize eYcacy, two courses of adjuvant chemotherapy
have turned out to be the best for reaching the goal of
cure. Therefore, risk-adapted management with adjuvant123
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NSGCT seems appropriate. EVorts are being made to fur-
ther reduce toxicity, and the application of just one single
course of BEP may turn out to be the future standard if
ongoing trials conWrm existing results.
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